Vijayapura

Researchers are investigating the effects of two different mixes combining Human Milk Oligosaccharide 2'-O-fucosyllactose (HMO-2FL) with Humiome4 Post LB postbiotic on gastrointestinal symptoms in adults with Irritable Bowel Syndrome (IBS). This randomized, placebo-controlled, double-blind trial aims to compare these formulations to a placebo to see how they impact symptoms such as abdominal pain, bloating, and bowel movements. The study also evaluates quality of life, gut health biomarkers, and safety in participants aged 18 to 70 years. Participants will be randomly assigned to one of three groups: one group will take Mix 1 containing 300 mg of Humiome4 Post LB postbiotic and 300 mg of HMO-2FL as one capsule daily; another group will take Mix 2 with 100 mg of Humiome4 Post LB postbiotic and 500 mg of HMO-2FL once daily; the third group will receive a placebo capsule daily. The treatment period lasts 6 weeks, during which participants take the assigned capsule orally every day. Throughout the study, participants will undergo assessments using the IBS Symptom Severity Scale at the start and after 6 weeks to measure changes in symptoms. They will also complete questionnaires about their quality of life and provide samples for gut health markers. Safety monitoring will be conducted, and participants will use an app-based digital diary to record their symptoms and treatment adherence. The total duration of participation covers the 6-week treatment and evaluations before and after the treatment period.